PCVX Quote, Financials, Valuation and Earnings

Citius Oncology has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat Citius Oncology's return on equity of --.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 268.88%. On the other hand Citius Oncology has an analysts' consensus of $3.00 which suggests that it could grow by 12.78%. Given that Vaxcyte has higher upside potential than Citius Oncology, analysts believe Vaxcyte is more attractive than Citius Oncology.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Citius Oncology pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Citius Oncology quarterly revenues of --. Vaxcyte's net income of -$140.7M is lower than Citius Oncology's net income of -$7.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while Citius Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for Citius Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Vaxcyte's net margin of -907.48%. Vaxcyte's return on equity of -- beat Moderna's return on equity of -29.23%.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 268.88%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 77.58%. Given that Vaxcyte has higher upside potential than Moderna, analysts believe Vaxcyte is more attractive than Moderna.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Moderna quarterly revenues of $107M. Vaxcyte's net income of -$140.7M is higher than Moderna's net income of -$971M. Notably, Vaxcyte's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 3.32x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -- compared to Vaxcyte's net margin of 82.81%. Vaxcyte's return on equity of -- beat Novavax's return on equity of --.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 268.88%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 106.91%. Given that Vaxcyte has higher upside potential than Novavax, analysts believe Vaxcyte is more attractive than Novavax.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Novavax quarterly revenues of $626.3M. Vaxcyte's net income of -$140.7M is lower than Novavax's net income of $518.6M. Notably, Vaxcyte's price-to-earnings ratio is -- while Novavax's PE ratio is 2.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 0.89x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Vaxcyte's net margin of -60.08%. Vaxcyte's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

Vaxcyte has a consensus price target of $125.75, signalling upside risk potential of 268.88%. On the other hand Sarepta Therapeutics has an analysts' consensus of $48.04 which suggests that it could grow by 153.1%. Given that Vaxcyte has higher upside potential than Sarepta Therapeutics, analysts believe Vaxcyte is more attractive than Sarepta Therapeutics.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Vaxcyte's net income of -$140.7M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Vaxcyte's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 0.94x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.